<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382654</url>
  </required_header>
  <id_info>
    <org_study_id>033-102</org_study_id>
    <secondary_id>033-102</secondary_id>
    <nct_id>NCT01382654</nct_id>
  </id_info>
  <brief_title>Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The objectives of this study were to:

        -  Examine the tolerability of two formulations and two dose concentrations of epinastine.

        -  Select formulation(s) of epinastine for future studies by evaluating the individual
           sensory attribute scores of the Nasal Spray Evaluation Questionnaire (NSEQ) collected
           after each study drug administration and the subject preference ranking assessed at the
           completion of the study.

        -  Compare the preference of two formulations and two dose concentrations of epinastine
           compared to azelastine following a single dose of each in a randomized, double-blind,
           two-cohort, three-period crossover design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall preference rank at the completion of the study using the Overall Nasal Spray Evaluation Questionnaire (NSEQ)</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores from each individual response from the NSEQ of all administered formulations (two formulations and two concentrations of epinastine and azelastine).</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>epinastine 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epinastine 0.1% with taste masking agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epinastine 0.2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epinastine 0.2% with taste masking agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastine 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nasal spray 2 sprays in each nostril for a total of 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinastine 0.1%</intervention_name>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
    <arm_group_label>epinastine 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinastine 0.1% with taste masking agent</intervention_name>
    <description>nasal spray 2 sprays to each nostril for a total for a 3 doses</description>
    <arm_group_label>epinastine 0.1% with taste masking agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinastine 0.2%</intervention_name>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
    <arm_group_label>epinastine 0.2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinastine 0.2% with taste masking agent</intervention_name>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
    <arm_group_label>epinastine 0.2% with taste masking agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine 0.1%</intervention_name>
    <description>nasal spray 2 sprays to each nostril for a total of 3 doses</description>
    <arm_group_label>azelastine 0.1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between ages 18-70

          -  history of SAR or PAR for 1 year

          -  mild symptoms

        Exclusion Criteria:

          -  asthma or RAD

          -  respiratory tract infection within 14 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <disposition_first_submitted>June 24, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 24, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2011</disposition_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelastine</mesh_term>
    <mesh_term>Epinastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

